Page 3 - Roche Group News Today

Approximately one in five people worldwide have elevated Lp(a) levels, putting them at increased risk of cardiovascular diseases including myocardial infarction and stroke.1The Roche Diagnostics Tina-quant®

Press release - Verified Market Reports - Food for Special Medical Purpose (FSMP) Market Size, Potential Scope 2031 By Major Players- Nestle, Danone Nutricia, Abbott, Bayer, MeadJohnson - published on openPR.com

The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the...

The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line

Filed Pursuant to Rule 424 Registration No. 333-277758 PROSPECTUS SUPPLEMENT Up to $39,966,424...

MAINZ, Germany, May 21, 2024 - BioNTech SE(Nasdaq: BNTX, "BioNTech" or "the Company") will present clinical trial data for selected programs from the Company's diversified immuno-oncology pipeline at the

Investegate announcements from BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024

Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced updates to its 2nd Annual Spinal Cord Injury Investor Symposium ("2nd SCIIS"). The 2nd SCIIS aims...

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target ...

The SON-1010 studies have together enrolled 61 subjects, to date, as dose escalation continues in SB101 and SB221 at higher levelsPatients have received up to 25 cycles of SON-1010 as monotherapy and 10